Email Us
Call Us
Dose range finding establishes the doses at which a test article can be administered without unacceptable toxicity, and it is the study on which almost everything that follows depends. An efficacy study dosed above the tolerated range loses animals and produces confounded data. A definitive toxicology study with poorly chosen dose levels either shows no findings at any dose or shows unmanageable toxicity at all of them, and in both cases must be repeated at full cost.
Altogen Labs conducts dose range finding and maximum tolerated dose studies in mouse and rat as a discrete preliminary step ahead of efficacy and definitive safety work. Running it separately is substantially cheaper than absorbing the consequences of a wrong dose inside a fully powered study. To discuss a dose range finding design, request a quote.
Study design
Escalating doses are administered to small cohorts, with the starting dose and escalation factor selected from available in vitro data, structural class, and any prior in vivo experience with the compound or a close analogue. Design may be single dose, repeat dose over a defined period, or both, depending on whether the subsequent study involves acute or chronic administration, since tolerability of a single dose says little about tolerability of the same dose given daily for three weeks.
Route and formulation match those intended for the subsequent study. A compound tolerated intraperitoneally may not be tolerated orally at the same dose, and a formulation change between the range finding study and the efficacy study invalidates the dose selection it was run to support.
Endpoints
Body weight is followed throughout, with a defined percentage loss triggering intervention. Clinical observations are recorded to a structured scoring system rather than noted informally, since the difference between mild and moderate signs determines dose selection and requires consistent criteria between observers.
Where the compound class or an observed signal warrants it, clinical chemistry and hematology identify the organ systems involved, and histopathology establishes whether a biochemical signal has a tissue correlate. These frequently detect an effect before body weight moves, which allows a dose to be excluded on the basis of a mechanism rather than on a clinical sign alone.
Defining the maximum tolerated dose
Maximum tolerated dose is a defined endpoint, not an impression, and the definition is agreed before the study opens. Typical criteria combine a body weight loss threshold, absence of severe clinical signs, and absence of mortality, with the specific thresholds set for the species, strain, study duration, and the intended use of the result. A dose selected against undefined criteria cannot be defended later.
Applied examples
Dose selection for efficacy. Three escalating doses are administered over a repeat-dose period matching the intended efficacy schedule, identifying the highest dose producing acceptable weight change, which becomes the high dose in the efficacy study rather than a dose estimated from in vitro potency.
Route comparison. The same compound is assessed by two routes at matched dose, establishing that the intended route is tolerated at the exposure the program requires before the efficacy study is designed around it.
Early organ signal. Interim clinical chemistry identifies hepatic enzyme elevation at the top dose before any body weight change, allowing that dose to be excluded and the definitive study to proceed with an informed dose rationale.
Position in a development program
Dose range finding supports efficacy studies, in vivo pharmacology, and IND-enabling programs, and is typically run alongside early exposure characterization so that the tolerated dose and the exposure it produces are known together.
Protocol definition and conduct
Dose levels, escalation criteria, stopping rules, observation schedule, endpoint definitions, and humane endpoints are specified before initiation, since escalation decisions made during a study without pre-agreed criteria are difficult to justify afterward. All procedures are conducted under active IACUC protocols, with animal numbers held to the minimum consistent with the objective and escalation designs used in preference to parallel high-dose groups where appropriate. GLP standards are applied where a study is formally designated as GLP; exploratory dose range finding is frequently conducted to non-GLP standards by design, and the designation is agreed at the outset.
Send compound, intended route, and the study the dose selection will support, or request a quote.